Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Monday, September 23rd. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Down 5.1 %

NASDAQ MRNS opened at $0.27 on Thursday. The stock has a 50 day moving average price of $0.75 and a 200-day moving average price of $1.18. Marinus Pharmaceuticals has a one year low of $0.26 and a one year high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd bought a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at about $34,000. AQR Capital Management LLC boosted its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth about $64,000. Finally, Values First Advisors Inc. increased its position in shares of Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares during the period. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.